Proacta Garners $1,100,000 New Financing Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    9255 Towne Centre Drive San Diego, CA 92121
  • Company Description
    Proacta is developing a new generation of cancer drugs that uniquely target physiological attributes of solid tumors.

    Proacta’s first lead program, a hypoxia targeted small-molecule prodrug, is designed to improve the outcomes of current treatment regimens, including chemotherapy and radiotherapy. PR-104 is in Phase I clinical trials and planned to begin in a second Ph I study and a Ph II study for 2006. The second compound is planned to enter the clinic in 2007.

  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor

Trending on Xconomy